Atlas Trials

Study of Eteplirsen in Young Participants With Duchenne Muscular Dystrophy (DMD) Amenable to Exon 51 Skipping

Clinical trial NCT03218995 · COMPLETED

Trial details

NCT number
NCT03218995
Sponsor
Sarepta Therapeutics, Inc.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Duchenne Muscular Dystrophy
Start date
2017-08-16
Primary completion
2021-03-10
Enrollment
15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.